Jazz plays on as Xyrem challenges quashed

15-01-2015

Jazz plays on as Xyrem challenges quashed

racorn / Shutterstock.com

The US Patent and Trademark Office (USPTO) has rejected several petitions that challenged a patent covering Jazz Pharmaceuticals’ narcolepsy drug Xyrem (sodium oxybate).


PTAB, AIA, Xyrem, covered business method patent, Jazz Pharmaceuticals

LSIPR